Resume Writing Made Simple?

Posted in BioBusiness, BioJobBuzz, Career Advice

The first step in any job search is to ensure that your resume or curriculum vitae (CV) is ready for submission to prospective employers. For those of you who may still be struggling with the difference between a resume and a CV, a resume is usually a 1-2 page synopsis of who you are, where you have been and what you have done. In contrast, a CV is a much longer document that does the same thing as a resume but in much greater and granular detail. For most scientific positions a CV is the preferred document style. However, in some cases, employers may request a resume so pay attention before you submit your application.

While most people believe that a resume or CV is simply a list of your education, skillsets and experience, there is a preferred style, format and way to write a resume/CV that will enhance the possibility of securing a interview for the position. That said, it takes many years of resume/CV writing to perfect the process–something that many of you may not have time to do.  If you are unsure about how to write a resume/CV or have not updated your “paper” in many years, the quickest way to being applying for jobs is to hire a professional resume/CV writer to do it for you.  Generally speaking, this will cost anywhere from $200-$500.  Sadly, many graduate students and postdocs don’t have the money to invest in resume writing and in many cases are unable to craft a job winning resume/CV.

If you are unable to hire a resume writing professional, I came across a DIY solution called Scientific Resumes. Apparently this service company exclusively caters to graduate students and postdocs looking for resume/CV writing help.  In addition to their automated self-help products, they offer resume proofreading services and I suspect customized resume/CV writing too.  I have not used or carefully evaluated their products but it may be worth a visit to their website.

Until next time…

Good Luck and Good Job Hunting!!!!

How to Find a Job in the Legal Cannabis Industry

Posted in BioBusiness, Career Advice

According to a recent report by the Cannabis website Leafly, America’s legal cannabis industry now supports more than 122,000 full-time jobs in 29 States and Washington DC. I

A recent article by Bruce Barcott entitled “How to Find a Job in the Cannabis Industry” offers some insights on the types of jobs that are available and how to land one.

He offered, like most industries the best way to land a job in the Cannabis industry is to network yourself into one. Also, working with a recruiting firm can be helpful.  Interestingly, recruiting firms and staffing companies that specialize in Cannabis jobs are popping up daily in many states where medical and recreational Cannabis are legal. However, before you take the plunge it is important to educate yourself to determine what is out there and whether or not you are a good fit for a Cannabis career.

So what do we know?  Most of the open jobs are in the Western states, California, Colorado, Oregon, Washington, Nevada and Arizona with a growing presence in Minnesota and Massachusetts. There are a smattering of jobs emerging in New York, Connecticut, Maryland  and Washington DC.  While 40 percent of open positions are specific to the Cannabis industry, roughly 60 are jobs that exist in other industries such as executive assistants, human resources specialists retail operations directors bookkeepers and staff accountants.That said, there are a number of Cannabis business operators who are looking for pharmaceutical sales representatives, or in horticulturalists from large commercial plant growing operations.

So question is: are there are any jobs in the Cannabis for the average Bio Job Blog reader?  The answer is YES!!!!!!  Here are a few examples: Laboratory chemist, operations manager, analytical chemist/production manager, software developer, food productions manager, and my favorite professional joint roller.  Of course there will be many more opportunities as the industry continues to grow (pun intended). That said, relocation is likely required but then again if you are qualified and possess the skills the company may offer a relocation package.  There is a ton of money being made in the industry!

Until next time…

Good Luck and Good Job Hunting!!!!!

 

The Trump Effect? Macy’s to Shed 10,000 Jobs and Close Stores

Posted in BioBusiness, BioJobBuzz

Over the past few weeks, President-elect Donald Trump has taken much credit for saving several hundred US manufacturing jobs in Indiana. Also, he has excoriated car marker executives ranging from General Motors to Ford to Toyota for planning to build manufacturing facilities in Mexico. While it is not clear how many jobs Trump actually saved or whether his twitter rants prevented car manufacturers from setting up production plants in Mexico, it is clear that he cannot or will not save large numbers of American jobs in the retail/service sectors. To that point, Macy’s, last week, announced that it was shedding 10,000 jobs and closing 100 stores to cut costs to improve its bottom line.

You may ask why saving a few hundred air conditioning jobs at taxpayer expense more important than saving 10,000 American retail jobs? As you may recall, in the summer of 2015 Macy’s CEO Terry Lundgren  said that he would stop selling Donald Trump’s clothing line in all of its stores.  Lundgren decided to take this action because then candidate Trump said many Mexican immigrants were rapists or murderers. Shortly after Lundgren announced his decision, Trump called on his supporters to boycott Macy stores.

While it is unlikely that the Trump boycott was responsible for Macy’s decline (all department stores are are getting hammered by online retailers), I do not expect Trump to help Macy’s (like he helped Carrier) save any of the 10,000 jobs that will be lost.  This is because Trump is a vindictive and hateful man who will not help anyone unless they shower him with adulation or do as they are told. Further, he likely considers Terry Lundgren a “loser’ because his business is failing. And, if Donald was in charge,  Macy’s would be a HUGE and GREAT success. Put simply, Macy’s got what it deserves for dropping Trump’s clothing line and not reinstating it after Trump was elected President. And, as for Lundgren, he said

“We made our decision about a year and a half ago, and stand by our decision,”

It’s going to be a rocky ride for the next 4 years.  So buckle in and hold on for your life!

Until next time…..

Good Luck and Good Job Hunting!!!!!!!!!!

Researchers Beware of Fake Journal and Conference Companies

Posted in BioBusiness, BioJobBuzz, Career Advice

Fake news seems to be de rigueur these days and apparently academia is not immune. In fact, increased competition for grants, publications and exposure may make academic researchers more susceptible to fake journals and dishonest conference organizers.  This is according to an article in today’s New York Times entitled ‘Fake Academe, Looking Much Like the Real Thing’

One of the leading fake purveyors of fake journals and bogus conferences is a Hyderabad, India -based company called OMICS International. I’m sure may BioJobBlog readers have been contacted or solicited by the company to attend a conference or submit a paper to one of its journals. This year, the Federal Trade Commission formally charged OMICs with “deceiving academics and researchers about the nature of its publications and hiding publication fees ranging from hundreds to thousands of dollars.”

According to the Times article, fake journals and bogus conference schemes;

…exploit a fundamental weakness of modern higher education: Academics need to publish in order to advance professionally, get better jobs or secure tenure. Even within the halls of respectable academia, the difference between legitimate and fake publications and conferences is far blurrier than scholars would like to admit

Another fake or close to fake organization is a British company called Infonomics Society which publishes 17 journals and organizes conferences. Interestingly, all 17 journals and conference organized by the company are run and managed by a single individual from a modest home in one of London’s outer suburbs. Other companies and several universities that have been scammed by these companies are also mentioned in the article.  

It is becoming increasingly important in the digital age to carefully vet websites and organization you do business with.  While the pressure for grant monies and publication in high impact journals continue to grow, it is important to remember that there are no shortcuts that can be taken to expedite a successful academic career.  The only things that will ensure success are commitment, hard work and some blood sweat and tears.

Until next time…..

Good Luck and Good Job Hunting

Trump, Once Again, Falsely Takes Credit for New US Job Creation

Posted in BioBusiness, Career Advice

As  you may recall, one of Trumps major campaign messages to his followers was to”force corporate America to focus on job creation at home rather than abroad.”  In my opinion, Trump’s possible success as President is and will continue to be inextricably linked to fulfilling his promise to create new jobs for out-of-work or underemployed Americans. That said, Trump will do or say anything, including taking false credit, to show his supporters that he can indeed create US jobs.

Yesterday, Trump announced:

I was just called by the head people at Sprint, and they are going to be bringing 5,000 jobs back to the United States,” Mr. Trump told reporters at his Mar-a-Lago estate in Florida. “They have taken them from other countries. They are bringing them back to the United States.”

Later in the day, Sprint said that the jobs were part of a previously announced commitment by Japan’s Soft Bank, which owns a controlling interest in Sprint, to invest $50 billion in the US and create 50,000 new jobs. As you may recall, shortly after electoral college win, Trump met with Masayoshi Sun, the CEO of Softbank who made the announcement and quickly took credit for the announced investment. Interestingly, the investment and job creation plans predated the election. Put simply, the deal was forged long before Trump got involved.

Not withstanding Trump’s penchant for mendacity, it is important to note that since the election, Sprint stock price has risen by 40%, partly on the hopes that it will be acquired by its rival cellphone carrier T-Mobile. While the Obama administration frowned upon telecom mergers because of anti-trust concerns, Sun and his investors believe that the Trump administration may look more favorably on any potential deals with T-mobile or other players in this sector.

Moreover, last January, as part of a restructuring effort, Sprint cut 2,500 jobs in call centers throughout the US and its corporate headquarters. This means that there will be a net gain of only 2,500 new Sprint jobs in the US if the announced positions are ever created or filled (supposedly by the end of fiscal year 2017). In any event, if a merger ultimately does take place between Sprint and T-Mobile, there are likely to be massive job cuts which typically occur after most mergers to reduce duplication of effort at both the technical and administrative levels.

Sadly, it is becoming increasingly evident that Trump is willing to lie or take credit for deals that have little or nothing to do with him when it comes to job creation (or anything else for that matter).  To that point, be wary of anything Trump says or does when it comes to job creation during his administration.  When the smoke clears and mirrors are removed, any announced job “deals”are likely to be in the best interests of corporate America; not hard-working or job-seeking Americans.

Until next time….

Good Luck and Good Job Hunting!!!!!!

Trump’s Corporate Tax Holiday Proposal Will Hurt Job Creation

Posted in BioBusiness, BioJobBuzz

The notion that corporate tax holidays– congressional orders that allow corporations like Apple, Microsoft, Pfizer and others to bring overseas profits back to the US without penalty–create jobs is misleading and, based on previous such tax holidays mostly untrue.

According to an article in today’s NY Times Business section (a reliable source of real news), corporate tax holidays typically result in mergers and acquisition that typically result in job cuts.

…the last time Congress initiated a tax holiday, in 2004. The top 15 repatriating companies brought home $150 billion but reduced their work force by 20,931 jobs, according to a 2011 study commissioned by the Senate Permanent Subcommittee on Investigations.

In the coming months, Trump and his minions will be pushing for a new corporate tax holiday so that new jobs can be created. While this is certains to send shivers down the spines of most Trump supports, any jobs that will be created or not lost will not be the ones that midwestern small town employees or coal mines will benefit from. For example, the  corporations with the largest amounts of overseas monies are Apple and Microsoft, two technology companies that are unlikely to create new jobs for coal miners, service employees or blue collar workers.

While many Trump supporters believe that Barack Obama and the Democrats were responsible for manufacturing job loss in the US, the real reasons for their loss was mechanization/robotization and globalization. The lost manufacturing jobs are never coming back–despite Trump’s assertions that they are—and the only way unemployed factory workers will find new work is through retraining or moving to urban centers where jobs for unskilled workers appear to be on the rise.  Corporate tax holidays, income tax cuts and reduction in social programs will not lead to new job creation but to job loss.

Don’t let Trump destroy the economic recovery that President Obama brought to this nation.

Until next time…

Good Luck and Good Job Hunting

Want to Keep Your Job and Get a PhD in the Trump Era? Unionize!!!!!!

Posted in BioBusiness, BioEducation, BioJobBuzz, Career Advice

It should come as no surprise that Donald Trump is anti-union and his recent cabinet pick for Secretary of Labor is clearly not a friend of working people.  Put simply, Trump is on the side of big business and employers. And if he and his billionaire friends can squeeze more work out of employees for lesser pay, then he and his administration gladly propose legislation to accomplish those goals. Also, don’t be shocked when Trump cuts the budgets of federal agencies that offer research grants, fellowships and teaching assistantships to American colleges and Universities.

It’s no secret that graduate students and postdocs are overworked and underpaid and long term career prospects continue to dwindle.  Further, during the course of my career advising graduate students and postdocs about job opportunities, I have heard too many horror stories about PIs who refuse to let their students or postdoc do anything outside of their laboratories to enhance careers or job opportunities.

While the public and private union movement is dying in the US, unions still offer exploited workers to negotiate their fates, working conditions, pay and benefits with employers.  Sadly, we in the academic community have been taught to be anti-union because of the high costs associated with union labor. Ironically, that is the point….why  should graduate students and postdocs not be fairly compensated for the long hours that they work?  Sure, you can say that graduate students will get a degree and postdocs need the experience to get a job but, while a degree and a postdoc in the past meant a good paying job in the end, no such guarantees exist today.  Basically, you are on your own!

Last week, graduate students at Columbia University overwhelmingly voted to unionize. According to a newspaper article in the NY Times:

The union will be the first to represent graduate students since the National Labor Relations Board ruled in August that students who work as teaching and research assistants have a federal right to unionize.

 

The vote to unionize was 1,602 to 623, according to the United Automobile Workers, which will now represent some 3,500 Columbia graduate students.

While the vote to unionize will undoubtedly upsets PIs, Deans and University Presidents, it is in the best career interests and lifestyles of graduate students and research assistants. For example, unions typically negotiate the salaries for 40 hour work weeks. We all know that postdocs and graduate students work more than 40 hours weekly. Therefore, any time over 40 hours ought to be overtime pay, or to avoid overtime hourly pay, base salaries have to be set a certain levels (according to Federal salary guidelines ) which are substantially more than what graduate students and postdocs are currently paid. Also, unions negotiate with employers about vacation times, benefits (health and life insurance,401K plans etc) and establish guidelines that protect employees from being abused by employers and create rules that guide whether or not an employee can be fired “for cause” (not simply because your employer does not like you).

As I previously mentioned, research budgets and public unions will likely be under constant attack during the Trump regime.  Because of this, it is time that everyone begins to think about ways in which they can protect their jobs and keep their career aspirations alive. I know it won’t be easy but as someone once said “desperate times require desperate measures” (or something like that).

Until next time….

Good Luck and Good Unionizing!!!!!!

Tis the Season: Astra Zeneca is the Latest Pharmaceutical Company to Announce Job Cuts

Posted in BioBusiness, BioJobBuzz

AstraZeneca announced today that it would be eliminate another 700 US job as part of its $1.1 billion cost saving plan that was implemented earlier this year. According to a Fierce Pharma report, the company will eliminate jobs throughout its US commercial operations and at its US headquarters in Wilmington, DE.

The latest job cuts come just days after London-based AstraZeneca mentioned that it would move some UK finance jobs to Malaysia, Costa Rica, Poland and other lower cost markets to consolidate back office work. Generic versions of the company’s top selling cholesterol lowering drug Crestor is what is driving financial concerns at the company. While there are other promising drugs in AZ”s pipeline and slated to appear on the market, their combined revenue will not be enough to fill the gap lost by Crestor and Nexium (which went generic last year).

Earlier this week Mylan, Endo and Perrigo announced job cuts. Isn’t it great to work in pharma around the holidays?

Until next time,

Good Luck and Good Job Hunting!!!!!!!!

Another Day: More Pharmaceutical Layoffs

Posted in BioJobBuzz, Uncategorized

Endo International PLC, a Dublin, Ireland-based global speciality pharmaceutical company that sells generic and branded prescription drugs, today announced that it plans to layoff 375 US sales employees most of whom work in its branded pain sales force. The company manufactures several branded opioid pain medicines including OPANA ER® and Percocet® Ostensibly, the job cuts will yield  will free up $90 to $100 million that the company will used to restructure and refocus its business units.

The ongoing very public national discussion about opioid abuse has caused Endo to re-evaluate its new product development strategy ( the company stock has been hemorrhaging over the past year or so). To that end, the company announced a new focus on the drug Xiaflex, a penis curvature drug that the company acquired in its $2.6 billion buyout of Auxilium.  By focusing on new markets, the company hopes to reduce its financial dependency on its legacy opioid business that has been waning as new legislation restricting patient access to opioids continues to be passed in States that have been devastating by the growing opioid epidemic sweeping the US.

Until next time…

Good luck and Good Job Hunting

 

It’s the Holiday Season: Time for More Job Cuts in Pharma

Posted in BioBusiness, BioJobBuzz

While the holiday season (beginning on Thanksgiving) is supposed to be joyous, it is usually the time of year that many life sciences and other large corporations announce job cuts. As expected, two companies, Mylan and Lilly announced today that they will be cutting the size of their work forces and laying off employee.

Mylan, whose CEO was forced to appear before Congressional committees because of the company’s egregiously high price it was charging for EpiPens, announced that it may lay off of as many as 3,500 workers. The reason for the layoffs was to “reduce redundancy” that resulted from Mylan’s $5.3 billion acquisition of Abbott Laboratories generic drug business, the $7 billion it paid to purchase the Swedish drugmaker Meda and the $1.0 billion for several topical skin medications from Renaissance Holdings. The layoffs will purportedly impact less than 10% of Mylan’s global workforce and help to cut costs and refocus operations at the generic drug manufacturer.

Likewise, troubled pharmaceutical manufacturer Lilly, whose CEO abruptly retired earlier this year announced that it was trimming its US pharmaceutical sales force. The announced cuts were related to the recent Phase 3 failure of the company’s Alzheimer’s project solanezumab. A company spokesperson did not disclose the number of sales representative who would lose their jobs.

Finally, this past September, the Danish company  Novo Nordisk, a world leader in the diabetes market, announced it would layoff 1,000 employees worldwide to cut costs and focus it efforts on developing “truly innovative” diabetes products.  Meanwhile, behind the scenes, speculation suggests that the layoffs are in response to payer pressures that are being brought to bear in the US, the company’s largest market.  Many of the cuts are expected in R&D where innovation has been lacking according to company executives.

Although these jobs cuts are taking place, the good news is that these workforce reductions are smaller than those announced in holiday seasons past!

Until next time

Good Luck and Good Job Hunting